Genzyme Again Beats Patients’ Lawsuit Over Fabrazyme Shortage

Genzyme Corp. defeated another round of litigation seeking to hold it responsible for a shortage of Fabrazyme, a drug that treats the genetic disorder Fabry disease, as a federal court in Massachusetts said most patients lacked standing and others didn’t adequately plead their claims.

Fabry disease patients lack an enzyme needed to break down fats. A Fabrazyme shortage some years ago led to a rationing program in which patients received less than the recommended dose.

Numerous patients, including lead plaintiff Trina Wilkins, had sued Genzyme previously, but the First Circuit rejected those claims for lack of standing in 2016.

Plaintiffs ...